跳至主要内容
临床试验/NL-OMON45898
NL-OMON45898招募中不适用

A phase I/II Study to Evaluate the Safety and Feasibility of Dual-modality imaging using Indium-111-DOTA-labetuzumab-IRDye800CW in patients with Peritoneal Carcinomatosis of Colorectal Origin - The DuMoPEC study

Radboud Universitair Medisch Centrum0 个研究点目标入组 29 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
29

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational invasive

入排标准

年龄范围
18 至 99(—)

入选标准

  • Clinical diagnosis of peritoneal carcinomatosis of colorectal origin.
  • Scheduled for cytoreductive surgery and HIPEC.
  • Age over 18 years
  • Signed informed consent

排除标准

  • Any medical condition present that in the opinion of the investigator will affect patients* clinical status.
  • Administration of a radionuclide within 10 physical half- lives prior to study enrollment
  • Pregnancy or lactation
  • Very high (>500 ng/ml) serum CEA levels
  • Immunohistochemically proven non-CEA expressing primary tumor (if analyzed in primary tumor resection specimen)

研究者

相似试验